CRL
Charles River Laboratories
290.20$
+1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.3% | -0.2% | +1.4% | -1.6% | -0.7% | -1.8% | +4.9% | -2.6% | -1.1% | +0.2% | +0.8% | – | |
| – | -2.3% | +2.7% | +0.9% | -1.7% | +8.7% | -7.2% | +1.3% | -1.3% | +3.0% | +4.4% | -10.6% | – | |
| – | +0.6% | -5.3% | +2.6% | -1.3% | -18.6% | +11.8% | +12.4% | -5.1% | -9.1% | -9.3% | +30.1% | – | |
| – | +11.9% | -5.5% | -8.9% | +17.3% | -1.8% | -9.2% | +7.7% | -7.3% | +5.7% | -15.0% | +43.6% | – | |
| – | +9.9% | -5.3% | -7.7% | +14.6% | +95.1% | -46.2% | +5.7% | -20.2% | -8.5% | -15.0% | +52.7% | – | |
| – | -12.3% | -5.2% | +20.4% | -22.6% | -242.8% | – | +34.1% | +33.6% | -10.1% | -0.3% | 0.0% | – | |
| – | -0.6% | +4.3% | -6.4% | -7.6% | -6.8% | -1.2% | +7.5% | -15.2% | -6.4% | +12.5% | +13.5% | – | |
| – | +84.9% | -52.6% | +20.8% | -23.7% | -337.6% | – | +98.5% | +22.1% | -437.3% | – | – | – | |
| – | -20.5% | +24.2% | +3.5% | -17.5% | -114.5% | – | +85.4% | +69.0% | -156.3% | – | – | – | |
| – | +114.1% | -64.0% | +33.7% | -23.7% | -414.1% | – | +105.4% | +4.0% | -608.2% | – | – | – | |
| – | +43.1% | -32.0% | +8.7% | -12.1% | -141.2% | – | +19.9% | -10.5% | -197.1% | – | +135.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.